DGX Quest Diagnostics Incorporated Common Stock
$245,07
Harga · Agu 24, 2026
Fundamental per Jul 23, 2026
Rentang 52M
$171–$246
99% of range
Peringkat Analis
HOLD
23 analysts
Target Harga
$246
+0% upside
P/E (TTM)
28.3
ROE
14.2%
Margin Laba Bersih
9.0%
Tentang Quest Diagnostics Incorporated Common Stock Tinjauan perusahaan dari Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Baca selengkapnya
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
DGX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$245.07
Kapitalisasi Pasar
$27.20B
P/E (TTM)
28.3
EPS (TTM)
$8.75
Pendapatan (TTM)
$11.04B
Imbal Hasil Dividen
1.3%
ROE
14.2%
D/E Utang/Ekuitas
0.8
Rentang 52M
$171 – $246
DGX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
Arus Kas Bebas
$1.36B
2016-12-31
→
2025-12-31
Margin
9.0%
2016-12-31
→
2020-12-31
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
DGX
Median Rekan
P/E (TTM)
28.3
26.5
P/S (TTM)
2.5
2.0
P/B
3.8
4.9
EV / EBITDA
15.3
—
Price / FCF (Harga / FCF)
20.0
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
DGX
Median Rekan
Operating Margin (Margin Operasi)
14.1%
—
Net Profit Margin (Margin Laba Bersih)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
DGX
Median Rekan
Debt / Equity (Utang / Ekuitas)
0.8
—
Current Ratio (Rasio Lancar)
1.0
1.6
Quick Ratio (Rasio Cepat)
0.8
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
DGX
Median Rekan
Revenue YoY (Pendapatan YoY)
11.8%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
3.7%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
3.2%
—
EPS YoY
13.8%
—
Net Income YoY (Laba Bersih YoY)
13.9%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
DGX
Median Rekan
Payout Ratio (Rasio Pembayaran Dividen)
35.6%
—
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
Imbal Hasil Dividen
1.3%
Rasio Pembayaran Dividen
35.6%
CAGR Dividen 5T
—
| Tanggal ex-dividen | Jumlah |
|---|---|
| 8 Juli 2026 | $0,8600 |
| 6 April 2026 | $0,8600 |
| 13 Jan. 2026 | $0,8000 |
| 3 Okt. 2025 | $0,8000 |
| 7 Juli 2025 | $0,8000 |
| 7 April 2025 | $0,8000 |
| 14 Jan. 2025 | $0,7500 |
| 4 Okt. 2024 | $0,7500 |
| 8 Juli 2024 | $0,7500 |
| 5 April 2024 | $0,7500 |
| 16 Jan. 2024 | $0,7100 |
| 5 Okt. 2023 | $0,7100 |
| 10 Juli 2023 | $0,7100 |
| 6 April 2023 | $0,7100 |
| 17 Jan. 2023 | $0,6600 |
| 3 Okt. 2022 | $0,6600 |
| 5 Juli 2022 | $0,6600 |
| 5 April 2022 | $0,6600 |
| 18 Jan. 2022 | $0,6200 |
| 4 Okt. 2021 | $0,6200 |
DGX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
23 analis
- Beli Kuat 6 26,1%
- Beli 7 30,4%
- Tahan 10 43,5%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
15 analis · 2026-08-23
Median
$250.00
Sekarang
$245.07
Rendah
$204.00
Tinggi
$265.00
Target median
$250.00
+2,0%
Target rata-rata
$245.87
+0,3%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.09%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $3.12 | $2.85 | 0.27% |
| 31 Maret 2026 | $2.50 | $2.37 | 0.13% |
| 31 Des. 2025 | $2.42 | $2.38 | 0.04% |
| 30 Sep. 2025 | $2.60 | $2.53 | 0.07% |
| 30 Juni 2025 | $2.62 | $2.60 | 0.02% |
| 31 Maret 2025 | $2.21 | $2.17 | 0.04% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Neraca 27
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Arus Kas 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Profitabilitas 8
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Tingkat Pertumbuhan 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Laporan Laba Rugi 16
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Neraca 26
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Arus Kas 16
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Valuasi (TTM) 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Margin Operasi % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Laba Bersih | $992M | $871M | $854M | $946M | $2.00B |
| EPS Dilusian | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Rasio Lancar | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Rasio Cepat | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $1.36B | $909M | $864M | $1.31B | $1.83B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 1.176 pengaju · $12.9B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 115 (-25 vs Kuartal sebelumnya) | 64 (-17 vs Kuartal sebelumnya) | 415 (+69 vs Kuartal sebelumnya) | 333 (-20 vs Kuartal sebelumnya) | +7.5M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 11,93% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 10,11% | Saham |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 9,10% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $584.135.885 | 2.767.754 | 4,54% | Saham |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 3,71% | Saham |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 3,11% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $357.050.202 | 1.684.597 | 2,78% | Saham |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 2,57% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 2,42% | Saham |
| NORGES BANK | $298.133.109 | 1.406.620 | 2,32% | Saham |
| FMR LLC | $227.315.614 | 1.072.496 | 1,77% | Saham |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 1,35% | Saham |
| M&G PLC | $168.677.800 | 795.650 | 1,31% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 1,03% | Saham |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,95% | Saham |
| AMERIPRISE FINANCIAL INC | $109.652.758 | 517.352 | 0,85% | Saham |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,80% | Saham |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,80% | Saham |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,77% | Saham |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,76% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $91.995.201 | 434.042 | 0,72% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,71% | Saham |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86.608.697 | 407.302 | 0,67% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,65% | Saham |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,59% | Saham |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,57% | Saham |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,55% | Saham |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,54% | Saham |
| Swiss National Bank | $65.683.305 | 309.900 | 0,51% | Saham |
| Balyasny Asset Management L.P. | $58.364.883 | 275.371 | 0,45% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56.877.630 | 268.354 | 0,44% | Saham |
| RHUMBLINE ADVISERS | $56.744.612 | 267.727 | 0,44% | Saham |
| BlackRock, Inc. | $55.976.419 | 264.102 | 0,44% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $54.809.634 | 258.597 | 0,43% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $53.654.295 | 253.146 | 0,42% | Saham |
| Quantinno Capital Management LP | $53.607.358 | 252.924 | 0,42% | Saham |
| RAYMOND JAMES FINANCIAL INC | $53.249.860 | 251.238 | 0,41% | Saham |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52.211.551 | 246.339 | 0,41% | Saham |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51.484.139 | 242.907 | 0,40% | Saham |
| Clark Capital Management Group, Inc. | $51.259.362 | 241.846 | 0,40% | Saham |
| Vanguard Global Advisers, LLC | $51.025.267 | 240.742 | 0,40% | Saham |
| Legal & General Group Plc | $50.185.731 | 236.781 | 0,39% | Saham |
| FIL Ltd | $49.419.958 | 233.168 | 0,38% | Saham |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49.341.000 | 232.797 | 0,38% | Saham |
| Eurizon Capital SGR S.p.A. | $47.173.414 | 222.564 | 0,37% | Saham |
| BARCLAYS PLC | $45.003.978 | 212.333 | 0,35% | Saham |
| PFA Pension, Forsikringsaktieselskab | $43.579.660 | 205.613 | 0,34% | Saham |
| Integral Health Asset Management, LLC | $42.390.000 | 200.000 | 0,33% | Saham |
| California Public Employees Retirement System | $41.574.204 | 196.151 | 0,32% | Saham |
| CONNING INC. | $39.578.271 | 186.734 | 0,31% | Saham |
| SEB Asset Management AB | $38.766.863 | 182.906 | 0,30% | Saham |
| BANK OF MONTREAL /CAN/ | $38.512.587 | 181.706 | 0,30% | Saham |
| GOLDMAN SACHS GROUP INC | $38.322.295 | 180.808 | 0,30% | Saham |
| Boston Partners | $35.509.632 | 167.514 | 0,28% | Saham |
| Focus Partners Wealth | $34.616.947 | 163.327 | 0,27% | Saham |
| STOREBRAND ASSET MANAGEMENT AS | $34.117.592 | 160.970 | 0,27% | Saham |
| COOKSON PEIRCE & CO INC | $32.977.089 | 155.589 | 0,26% | Saham |
| UBS Group AG | $32.934.699 | 155.389 | 0,26% | Saham |
| BRAUN STACEY ASSOCIATES INC | $32.724.232 | 154.396 | 0,25% | Saham |
| Willis Investment Counsel | $32.110.425 | 151.500 | 0,25% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31.795.403 | 162.238 | 0,25% | Saham |
| LPL Financial LLC | $30.325.576 | 143.079 | 0,24% | Saham |
| APG Asset Management N.V. | $27.869.580 | 150.334 | 0,22% | Saham |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26.893.912 | 126.888 | 0,21% | Saham |
| &PARTNERS | $26.382.365 | 124.363 | 0,21% | Saham |
| JANE STREET GROUP, LLC | $25.942.680 | 122.400 | 0,20% | Opsi beli |
| BANK OF AMERICA CORP /DE/ | $25.492.499 | 120.276 | 0,20% | Saham |
| Candriam S.C.A. | $25.459.925 | 120.238 | 0,20% | Saham |
| Squarepoint Ops LLC | $24.974.280 | 117.831 | 0,19% | Saham |
| Gotham Asset Management, LLC | $24.911.119 | 117.533 | 0,19% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.607.896 | 116.373 | 0,19% | Saham |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24.569.456 | 115.921 | 0,19% | Saham |
| Robeco Institutional Asset Management B.V. | $23.854.123 | 112.546 | 0,19% | Saham |
| AEGON ASSET MANAGEMENT UK Plc | $22.866.862 | 107.888 | 0,18% | Saham |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22.670.926 | 106.964 | 0,18% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.530.921 | 106.303 | 0,18% | Saham |
| MERCER GLOBAL ADVISORS INC /ADV | $22.106.507 | 104.301 | 0,17% | Saham |
| Moran Wealth Management, LLC | $22.053.609 | 104.051 | 0,17% | Saham |
| ABN AMRO Bank N.V. | $21.523.733 | 101.667 | 0,17% | Saham |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21.496.202 | 123.876 | 0,17% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.322.170 | 100.600 | 0,17% | Opsi beli |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.146.252 | 99.770 | 0,16% | Saham |
| AVIVA PLC | $20.378.569 | 96.148 | 0,16% | Saham |
| SCHWARTZ INVESTMENT COUNSEL INC | $20.326.005 | 95.900 | 0,16% | Saham |
| Boston Common Asset Management, LLC | $20.282.767 | 95.696 | 0,16% | Saham |
| CAPTRUST FINANCIAL ADVISORS | $20.146.790 | 95.054 | 0,16% | Saham |
| Midwest Trust Co | $20.113.207 | 94.896 | 0,16% | Saham |
| LAZARD ASSET MANAGEMENT LLC | $20.035.210 | 94.528 | 0,16% | Saham |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19.842.759 | 93.620 | 0,15% | Saham |
| BLAIR WILLIAM & CO/IL | $19.773.115 | 93.291 | 0,15% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19.613.005 | 92.536 | 0,15% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.160.280 | 90.400 | 0,15% | Opsi jual |
| CITADEL ADVISORS LLC | $18.821.160 | 88.800 | 0,15% | Opsi beli |
| WELLINGTON MANAGEMENT GROUP LLP | $17.507.282 | 82.601 | 0,14% | Saham |
| Foundry Partners, LLC | $17.338.432 | 102.473 | 0,13% | Saham |
| MARSHALL WACE, LLP | $17.187.874 | 81.094 | 0,13% | Saham |
| Coho Partners, Ltd. | $16.981.317 | 89.103 | 0,13% | Saham |
| Copeland Capital Management, LLC | $16.902.800 | 79.749 | 0,13% | Saham |
| CIBC Asset Management Inc | $16.674.318 | 78.671 | 0,13% | Saham |
| Mitsubishi UFJ Trust & Banking Corp | $16.558.594 | 78.125 | 0,13% | Saham |
Orang dalam perusahaan 53 orang dalam · 26 pejabat · 26 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1 Juni 2026 S | 132.423 | 0 | 5 | $-14.656.302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 April 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 Juli 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7 Maret 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5 Maret 2013 F | 126.722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 Juli 2026 S | 10.335 | 0 | 1 | $-376.288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 Juli 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 Juli 2026 L | 15.293 | 0 | 5 | $-2.390.549 |
| Catherine T. Doherty | EVP, Regional Businesses | 5 Maret 2026 S | 67.122 | 0 | 7 | $-6.671.228 |
| Michael E Prevoznik | SVP & General Counsel | 5 Maret 2026 S | 37.557 | 0 | 7 | $-6.505.199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4 Maret 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 Sep. 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7 Maret 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 Feb. 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1 Maret 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8 Maret 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1 Maret 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2 Maret 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 Feb. 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 Maret 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 Feb. 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 Juni 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 Feb. 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 Feb. 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 Feb. 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 Feb. 2004 F | 49.609 | 0 | 0 | $0 |
| Wright Lassiter III | Direktur | 22 Juli 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Direktur | 22 Juli 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Direktur | 22 Juli 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Direktur | 22 Juli 2026 L | 22.460 | 0 | 0 | $0 |
| Timothy C Wentworth | Direktur | 1 Juli 2026 A | 1.358 | 0 | 0 | $0 |
| Timothy M Ring | Direktur | 20 Mei 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Direktur | 20 Mei 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Luis Diaz | Direktur | 15 Mei 2025 A | 4.054 | 0 | 0 | $0 |
| Tracey Doi | Direktur | 15 Mei 2025 A | 6.490 | 0 | 0 | $0 |
| Gail R Wilensky | Direktur | 17 Mei 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Direktur | 6 Maret 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Direktur | 25 Mei 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Direktur | 23 Nov. 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Direktur | 4 Juni 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Direktur | 29 Mei 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Direktur | 22 Feb. 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Direktur | 12 Agu 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Direktur | 12 Feb. 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Direktur | 31 Jan. 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Direktur | 6 Mei 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Direktur | 1 April 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Direktur | 4 Mei 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Direktur | 28 April 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Direktur | 1 April 2004 A | 2.627 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 13 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 Mei 2011 | — | Pengajuan awal | M&A / penjualan | SEC |
| Orang pelapor yang tidak diungkapkan | 1 Feb. 2011 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 20 Maret 2009 | — | Pengajuan awal | — | SEC |
| GlaxoSmithKline plc ×2 pengajuan | 18 Sep. 2008 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 16 Feb. 2007 | — | Pengajuan awal | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 pengajuan | 19 Jan. 2006 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 15 Des. 2004 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 29 Juni 2004 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 24 Juni 2002 | — | Pengajuan awal | M&A / penjualan | SEC |
| Orang pelapor yang tidak diungkapkan | 22 Mei 2002 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 12 April 2002 | — | Pengajuan awal | M&A / penjualan | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 pengajuan | 1 Nov. 2001 | — | Pengajuan awal | M&A / penjualan | SEC |
| Orang pelapor yang tidak diungkapkan | 14 Mei 2001 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 194 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IHF · iShares Trust | 3,93% | 199.039 SH | 21 Agu 2026 | Harian |
| FTDS · First Trust Exchange-Traded Fund | 2,17% | 3.760 NS | 30 Juni 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,71% | 58.159 SH | 21 Agu 2026 | Harian |
| GK · AdvisorShares Trust | 1,43% | 2.156 NS | 30 Juni 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57.932 NS | 30 April 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,24% | 9.488 SH | 21 Agu 2026 | Harian |
| TMFX · RBB Fund, Inc. | 1,05% | 1.724 NS | 31 Mei 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 Mei 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196.208 NS | 31 Mei 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4.047 NS | 30 April 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 April 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,78% | 4.426 SH | 21 Agu 2026 | Harian |
| QLV · FlexShares Trust | 0,74% | 6.461 NS | 30 April 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 Mei 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 21 Agu 2026 | Harian |
| PAPI · Morgan Stanley ETF Trust | 0,56% | 10.542 NS | 30 Juni 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1.956 NS | 30 April 2026 | N-PORT |
| PRAY · FIS Trust | 0,47% | 1.958 NS | 31 Mei 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2.110 NS | 29 Mei 2026 | N-PORT |
| BTAL · AGF Investments Trust | 0,46% | 6.072 NS | 30 Juni 2026 | N-PORT |
| KNGZ · First Trust Exchange-Traded Fund VI | 0,44% | 1.301 NS | 30 Juni 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1.055 NS | 30 April 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409.814 NS | 30 April 2026 | N-PORT |
| FVD · First Trust Exchange-Traded Fund | 0,43% | 161.912 NS | 30 Juni 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3.999 NS | 31 Mei 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 65.931 SH | 21 Agu 2026 | Harian |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19 Agu 2026 | Harian |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8.682 NS | 30 April 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8.368 NS | 30 April 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 18.030 SH | 21 Agu 2026 | Harian |
| SUSA · iShares Trust | 0,35% | 59.963 SH | 21 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51.278 NS | 30 April 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23.030 NS | 30 April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19 Agu 2026 | Harian |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 21 Agu 2026 | Harian |
| RXL · ProShares Trust | 0,31% | 1.147 NS | 31 Mei 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2.194 NS | 30 April 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 Mei 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79.983 NS | 30 April 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7.703.000 | 19 Agu 2026 | Harian |
| IWS · iShares Trust | 0,25% | 166.379 SH | 21 Agu 2026 | Harian |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18.806 NS | 30 April 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8.995 NS | 30 April 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3.340 NS | 30 April 2026 | N-PORT |
| CVMC · Morgan Stanley ETF Trust | 0,23% | 1.137 NS | 30 Juni 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26.229 NS | 30 April 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4.242 SH | 21 Agu 2026 | Harian |
| DFVE · DoubleLine ETF Trust | 0,23% | 351 NS | 30 Juni 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19 Agu 2026 | Harian |
| EUSA · iShares, Inc. | 0,22% | 18.045 SH | 21 Agu 2026 | Harian |